Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Lung Injury - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H1 2015', provides an overview of the Acute Lung Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Acute Lung Injury Overview 10 Therapeutics Development 11 Pipeline Products for Acute Lung Injury - Overview 11 Pipeline Products for Acute Lung Injury - Comparative Analysis 12 Acute Lung Injury - Therapeutics under Development by Companies 13 Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 16 Acute Lung Injury - Pipeline Products Glance 18 Clinical Stage Products 18 Early Stage Products 19 Acute Lung Injury - Products under Development by Companies 20 Acute Lung Injury - Products under Investigation by Universities/Institutes 22 Acute Lung Injury - Companies Involved in Therapeutics Development 23 Altor BioScience Corporation 23 Apeptico Forschung und Entwicklung GmbH 24 BioMarck Pharmaceuticals, Ltd. 25 Carolus Therapeutics, Inc. 26 CompleGen, Inc. 27 FirstString Research, Inc. 28 GlaxoSmithKline Plc 29 Histocell S.L. 30 Navigen Pharmaceuticals, Inc. 31 Noxxon Pharma AG 32 S-Evans Biosciences, Inc. 33 Silence Therapeutics Plc 34 Stemedica Cell Technologies, Inc. 35 Therametrics holding AG 36 Xiber Science GmbH 37 Acute Lung Injury - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 ALT-836 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AP-301 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Atu-111 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Atu-112 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BC-1215 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BIO-10901 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 CGX-1037 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CT-2009 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 DasKloster-0141-01 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 DasKloster-1000-04 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 GSK-2586881 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 GSK-2862277 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 HC-016 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 LTI-02 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Mesenchymal Stem Cells - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 MG-53 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 NOXD-19 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 P- BEFizumab - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 S-1229 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules to Inhibit Arf6 for Multiple Diseases - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Stem Cell Therapy for Acute Lung Injury - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Stromal Cell Therapy for Acute Lung Injury - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TXA-302 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Xib-1301 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Acute Lung Injury - Recent Pipeline Updates 92 Acute Lung Injury - Dormant Projects 98 Acute Lung Injury - Discontinued Products 100 Acute Lung Injury - Product Development Milestones 101 Featured News & Press Releases 101 Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 101 Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 101 Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury 102 Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 103 May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 103 Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 104 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 105 Disclaimer 106
List of Tables
Number of Products under Development for Acute Lung Injury, H1 2015 11 Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2015 22 Acute Lung Injury - Pipeline by Altor BioScience Corporation, H1 2015 23 Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2015 24 Acute Lung Injury - Pipeline by BioMarck Pharmaceuticals, Ltd., H1 2015 25 Acute Lung Injury - Pipeline by Carolus Therapeutics, Inc., H1 2015 26 Acute Lung Injury - Pipeline by CompleGen, Inc., H1 2015 27 Acute Lung Injury - Pipeline by FirstString Research, Inc., H1 2015 28 Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H1 2015 29 Acute Lung Injury - Pipeline by Histocell S.L., H1 2015 30 Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 31 Acute Lung Injury - Pipeline by Noxxon Pharma AG, H1 2015 32 Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H1 2015 33 Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H1 2015 34 Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 35 Acute Lung Injury - Pipeline by Therametrics holding AG, H1 2015 36 Acute Lung Injury - Pipeline by Xiber Science GmbH, H1 2015 37 Assessment by Monotherapy Products, H1 2015 38 Number of Products by Stage and Target, H1 2015 40 Number of Products by Stage and Mechanism of Action, H1 2015 42 Number of Products by Stage and Route of Administration, H1 2015 44 Number of Products by Stage and Molecule Type, H1 2015 46 Acute Lung Injury Therapeutics - Recent Pipeline Updates, H1 2015 92 Acute Lung Injury - Dormant Projects, H1 2015 98 Acute Lung Injury - Dormant Projects (Contd..1), H1 2015 99 Acute Lung Injury - Discontinued Products, H1 2015 100
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.